IL–20 and its three receptors were expressed in our clinical specimens and in the PC–3 and LNCaP prostate cancer cell lines, which suggested both autocrine and paracrine effects of IL–20 on prostate tumors and contributions to the pathogenesis of prostate cancer. The gene discussed is IL20; the disease is prostate carcinoma.